Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $39.4M | $57.4M | $94.4M | $142M | $187M | $209M | $213M |
| Revenue growth | — | 45.5% | 64.6% | 50.2% | 31.9% | 11.9% | 1.6% |
| Gross profit | $31.8M | $44.9M | $77.5M | $116M | $152M | $168M | $170M |
| Gross margin | 80.6% | 78.3% | 82.1% | 82.0% | 81.2% | 80.4% | 79.8% |
| Operating income | -$3.54M | $855K | -$16.5M | -$34.8M | -$51.4M | -$55.7M | -$54.2M |
| Operating margin | -9.0% | 1.5% | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% |
| Net income | -$4.26M | -$3.67M | -$20.6M | -$42.8M | -$49.5M | -$55.7M | -$59.0M |
| Net margin | -10.8% | -6.4% | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| EPS (diluted) | -$0.13 | -$0.12 | -$0.43 | -$0.77 | -$0.81 | -$0.90 | -$0.93 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.67M | -$4.49M | -$17.2M | -$30.6M | -$34.6M | -$37.2M | -$16.0M |
| Capital expenditures | $1.21M | $1.07M | $2.71M | $14.8M | $11.5M | $11.6M | $13.5M |
| Free cash flow | -$8.88M | -$5.56M | -$19.9M | -$45.5M | -$46.0M | -$48.8M | -$29.5M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.1M | $18.1M | $106M | $19.5M | $13.0M | $11.3M | $10.7M |
| Total assets | — | $41.8M | $141M | $159M | $252M | $217M | $191M |
| Total liabilities | — | $41.0M | $47.7M | $98.5M | $114M | $104M | $103M |
| Long-term debt | — | $29.2M | $29.4M | $52.7M | $53.0M | $53.3M | $55.6M |
| Shareholders' equity | $3.16M | $776K | $93.1M | $60.5M | $138M | $113M | $87.3M |
| Retained earnings | — | -$21.4M | -$41.9M | -$84.7M | -$134M | -$190M | -$249M |
| Shares (wtd avg diluted) | — | 37.1M | 48.4M | 55.3M | 60.9M | 62.1M | 63.3M |
Every figure is extracted from TREACE MEDICAL CONCEPTS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.